V

Vistin Pharma ASA
OSE:VISTN

Watchlist Manager
Vistin Pharma ASA
OSE:VISTN
Watchlist
Price: 23.4 NOK
Market Cap: 1B NOK
Have any thoughts about
Vistin Pharma ASA?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Vistin Pharma ASA

Revenue
423.6m NOK
Cost of Revenue
-149m NOK
Gross Profit
274.6m NOK
Operating Expenses
-192m NOK
Operating Income
82.7m NOK
Other Expenses
-21.3m NOK
Net Income
61.4m NOK

Margins Comparison
Vistin Pharma ASA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
NO
Vistin Pharma ASA
OSE:VISTN
1B NOK
65%
20%
14%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
753.7B USD
81%
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
85%
44%
35%
US
Johnson & Johnson
NYSE:JNJ
342B USD
69%
28%
17%
US
Merck & Co Inc
NYSE:MRK
252.1B USD
77%
34%
19%
CH
Roche Holding AG
SIX:ROG
214.3B CHF
73%
32%
20%
UK
AstraZeneca PLC
LSE:AZN
170.1B GBP
82%
21%
13%
CH
Novartis AG
SIX:NOVN
178.4B CHF
75%
31%
35%
US
Pfizer Inc
NYSE:PFE
152.2B USD
71%
22%
7%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Vistin Pharma ASA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
NO
Vistin Pharma ASA
OSE:VISTN
1B NOK
20%
16%
26%
18%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
753.7B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
342B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
252.1B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
214.3B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
170.1B GBP
17%
6%
14%
12%
CH
Novartis AG
SIX:NOVN
178.4B CHF
45%
17%
24%
16%
US
Pfizer Inc
NYSE:PFE
152.2B USD
5%
2%
7%
8%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.